Dr. Stephanie Annett is a Senior Lecturer in the School of Pharmacy & Biomolecular Sciences at RCSI. Her research centres on the immunophilin protein FKBPL and the development of RNA-based therapeutics across obesity, metabolic disease, cancer, and inflammatory conditions such as psoriasis. She is a scientific founder of spin-out technologies and leads translational programmes that bring novel gene- and RNA-based treatments closer to the clinic. Dr. Annett’s academic leadership, industry engagement, and dedication to pushing science toward real-world impact mark her as a rising force in therapeutic innovation.
Gene Therapy for Parkinson’s
Parkinson’s Disease is the second most frequent, degenerative neurological condition affecting up to ten million worldwide and occurs through loss of dopamine-producing neurons. This project will examine the...
Lead: Dr. Niamh Connolly, Dr. Stephanie Annett, Prof. Jochen Prehn, Prof. Tracy Robson
